Search results
Results From The WOW.Com Content Network
v. t. e. In the United States, prescription monitoring programs ( PMPs) or prescription drug monitoring programs ( PDMPs) are state-run programs which collect and distribute data about the prescription and dispensation of federally controlled substances and, depending on state requirements, other potentially abusable prescription drugs.
Therapeutic drug monitoring (TDM) is a branch of clinical chemistry and clinical pharmacology that specializes in the measurement of medication levels in blood. Its main focus is on drugs with a narrow therapeutic range, i.e. drugs that can easily be under- or overdosed. [1] TDM aimed at improving patient care by individually adjusting the dose ...
The Ohio Automated Rx Reporting System (OARRS) is Ohio's state Prescription Monitoring Program (PMP) and is controlled by the Ohio State Board of Pharmacy. [1] The law permitting the Board of Pharmacy to create the PMP was signed on March 18, 2005, and became effective January 1, 2006. The OARRS program began operation on October 2, 2006.
The trial against AmerisourceBergen Corp, McKesson Corp and Cardinal Health Inc in Charleston, West Virginia, involves a lawsuit seeking more than $1 billion brought by the city of Huntington and ...
Pseudomyxoma peritonei ( PMP) is a clinical condition caused by cancerous cells (mucinous adenocarcinoma) that produce abundant mucin or gelatinous ascites. [1] The tumors cause fibrosis of tissues and impede digestion or organ function, and if left untreated, the tumors and mucin they produce will fill the abdominal cavity.
(Reuters) -Major U.S. drug distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc are not responsible for fueling an opioid epidemic in a part of West Virginia, a federal judge ...
May 30, 2024 at 2:16 PM. (Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it plans to restructure its food division starting in October helping it to oversee human food ...
McFadden v. United States, 576 U.S. 186 (2015), was a United States Supreme Court case in which the Court held that section 841 of the Controlled Substances Act requires the government to prove that to be in criminal violation, a defendant must be aware that an analogue defined by the Controlled Substance Analogue Enforcement Act with which he was dealing was a controlled substance.